Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds...
13 Février 2014 - 1:00PM
Access Wire
Toronto, Ontario -
February 13, 2014 - Theralase Technologies
Inc. (TSXV: TLT) reported today that a recently published
scientific paper demonstrated that its new family of Photo Dynamic
Compounds (PDCs) has been proven to significantly destroy 2 types
of bacteria (Staphylococcus aureus (s.
aureus) and Methicillin Resistant
Staphylococcus aureus (MRSA)) in low oxygen
atmospheres. The results are considered pivotal because the
Theralase PDCs efficacy has been validated in
both normal and low oxygen environments. Since the Theralase PDC
platform technology is able to be used in both bacteria and cancer
destruction, the described technology is offering a new paradigm
for destruction of low oxygenated cancerous tumours.
(Photodiagnosis Photodyn Ther.
Dec;10(4):615-25).
"The ability for the PDC technology to be effective in
low oxygen environments is considered to be an essential factor in
the recurrence and progression of non-muscle invasive bladder
cancer. This form of disease represents up to
75% of newly diagnosed bladder cancer cases accounting for more
than 386,000 cases and 150,000 deaths annually worldwide,"
said Dr. Arkady Mandel, Chief Scientific
Officer of Theralase Inc. Dr. Mandel continued:
"The abnormal decrease or the lack of oxygen
supply to cells and tissues is called hypoxia and commonly presents
in solid cancers, such as brain, bladder, breast, lung and
prostate. Hypoxic cancers are extremely aggressive, resistant to
standard therapies (chemotherapy and radiotherapy), and thus very
difficult to destroy. Tumor hypoxia is known to play a role in
cancer metastasis (spread) and resistance to therapy, as well as
the ability of cancer cells to escape destruction by the immune
system. The evidence supporting the Theralase PDC technology
represents a potential solution for hypoxic cancers. In our
work, we described a family of Theralase PDCs that have shown an
ability to switch their photoreactivity from a Type II reaction
(oxygen dependent) to a Type I (free radical mediated) reaction.
This is strategic to the Company in that a Type I reaction is
unique and opens the opportunity of using the PDCs beyond
sterilization and the treatment of superficial cancerous lesions to
the treatment of harder to treat tumours".
Dr. Lothar Lilge, Senior Scientist at
the Princess Margaret Cancer Centre, University Health Network
stated that, "In well oxygenated environments, these new PDCs
generate singlet oxygen, a dominant cytotoxic substance with close
to 100% efficacy, yet under hypoxia (low oxygen) conditions, they
display the remarkable ability to switch to a Type I or oxygen
independent cytotoxic substance owing to their ability to
simultaneously act as an excited state oxidant and reductant. The
intrinsic positive charge of the Ru(II) metal combined with the
oxygen independent light activated cytotoxicity demonstrated by
this family of PDCs opens a new strategy for destroying both
gram-positive and gram-negative bacteria regardless of oxygenation
level. Therefore, this has a significant impact on the destruction
of cancer cells by PDC technology, as a considerable fraction of
cancer will survive in low oxygen environments and according to the
literature this is one of the causes for recurrence of cancer post
therapy."
Dr. Michael Jewett,
Clinical Principal Scientific Investigator at Princess Margaret
Cancer Centre, University Health Network and University of Toronto
stated that, "I am extremely encouraged by the results of this
scientific work and the implications that it may have in the
destruction of bladder Transitional Cell Carcinoma, as the bladder
is traditionally known as a very low oxygen environment. There has
not been a new drug approved for bladder cancer since 1998 and I am
looking forward to working with the Theralase team to initiate a
Phase 1 / 2 clinical trial in 1Q2015."
About
Theralase Technologies Inc.
Theralase
Technologies Inc. designs, manufactures and markets patented,
superpulsed laser technology used in healing injured tissue and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration of numerous nerve, muscle and joint injuries.
Theralase is actively developing patented technology that is able
to target and destroy cancers, bacteria and viruses when light
activated.
Additional
information is available at www.theralase.com and
www.sedar.com .
This press release
contains forward-looking statements, which reflect the Company's
current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information, please
contact:
Roger Dumoulin-White,
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024